Capricor Therapeutics Inc - CAPR STOCK NEWS

Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a preclinical study in Microbiology Spectrum, showcasing the potential of its StealthX™ exosome platform to develop a multivalent vaccine targeting SARS-CoV-2 proteins. The study indicates that engineered exosomes expressing SARS-CoV-2 spike and nucleocapsid proteins can induce strong immune responses. Notably, the combination approach (STX-S+N) demonstrated robust antibody production and T-cell response with minimal protein doses, lacking adjuvants. CEO Linda Marbán highlighted the significance of this platform in generating potentially superior vaccines. The results support further exploration of the StealthX™ platform in expanding Capricor's therapeutic pipeline, especially concerning rapidly evolving viruses.

Capricor Therapeutics (NASDAQ: CAPR) reported promising 18-month results from its HOPE-2 open-label extension study for CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). Presented by Dr. Craig McDonald at the Muscular Dystrophy Association Clinical & Scientific Conference, the findings show statistically significant improvements in the Performance of the Upper Limb (PUL version 2.0) scale (p=0.02) compared to the placebo group. Both groups showed reduced disease progression after starting treatment. CAP-1002 maintained a good safety profile, and the study indicates potential long-term benefits for patients. The company is advancing to the HOPE-3 Phase 3 trial.

Capricor Therapeutics (NASDAQ: CAPR) reports progress in its HOPE-3 Phase 3 trial for CAP-1002 in Duchenne Muscular Dystrophy (DMD), with enrollment exceeding 30% and an interim analysis expected in Q4 2023. The company also engaged with the FDA for a Biologics License Application (BLA) pathway. A partnership with Nippon Shinyaku expands its DMD franchise in Japan, yielding $12 million upfront and potential milestones of $89 million. Financially, Q4 2022 revenue was approximately $1 million, with a net loss of $7.7 million. Capricor's cash and equivalents totaled $41.4 million, sufficient to fund operations into Q4 2024.

Capricor Therapeutics (NASDAQ: CAPR) will announce its financial achievements for the fourth quarter and full year 2022 on March 15, 2023, following the market close. The company is expected to discuss its developments regarding CAP-1002, its leading candidate for treating Duchenne muscular dystrophy, currently in late-stage clinical trials. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and recent corporate updates. Investors can access the live webcast and replay through the company’s website.

Capricor Therapeutics (NASDAQ: CAPR) announced that its HOPE-2 trial for Duchenne muscular dystrophy using lead asset CAP-1002 has received the 2023 Top Ten Clinical Research Achievement Award from the Clinical Research Forum. This recognition highlights significant advancements in clinical research and underscores the promising results from the trial. Dr. Linda Marbán, CEO of Capricor, emphasized the commitment to bringing CAP-1002 closer to market. The award ceremony is scheduled for April 17, 2023, in Washington, D.C. DMD affects approximately 200,000 boys and young men globally, with limited treatment options available.

Capricor Therapeutics (NASDAQ: CAPR) has expanded its partnership with Nippon Shinyaku for the exclusive commercialization of CAP-1002 in Japan, targeting Duchenne muscular dystrophy (DMD). The agreement includes a $12 million upfront payment and potential milestone payments of up to $89 million, along with a double-digit percentage of product sales. Capricor remains responsible for clinical development, while Nippon Shinyaku will handle distribution upon approval. CAP-1002 has demonstrated clinical benefits for cardiac and skeletal muscle myopathy, underscoring its potential as an anchor therapy for DMD patients.

Capricor Therapeutics (NASDAQ: CAPR) announced positive 18-month results from its HOPE-2 open label extension study, showcasing significant improvements in the Performance of the Upper Limb (PUL 2.0) scale (p=0.02) for patients with Duchenne muscular dystrophy (DMD). The study indicated potential disease modification, with both original treatment and placebo groups experiencing slowed disease progression once treatment commenced. A total of 12 patients completed the follow-up, with CAP-1002 maintaining a consistent safety profile. Capricor is conducting a pivotal Phase 3 trial (HOPE-3) and aims for regulatory approval of CAP-1002 for DMD treatment.

Capricor Therapeutics (NASDAQ: CAPR) will present 18-month data from its ongoing HOPE-2 open-label trial for CAP-1002, targeting Duchenne muscular dystrophy (DMD). The webinar is scheduled for January 25, 2023, at 1:00 p.m. ET, in collaboration with Parent Project Muscular Dystrophy (PPMD). CAP-1002 is a cardiac-derived cell therapy currently in late-stage clinical trials for DMD treatment. This presentation aims to share significant findings and ongoing research developments. A replay will be available on PPMD's website. For further details, visit www.parentprojectmd.org.